This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Regeneron (REGN) Q1 Earnings Beat on Strong Eylea & Dupixent
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings while sales record strong year-over-year growth on solid performance of Dupixent and Eylea, and incremental contribution from REGEN-COV.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechs medical pharmaceuticals
bluebird (BLUE) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
bluebird (BLUE) reports a wider-than-expected loss for the first quarter of 2021 while revenues beat estimates.
BMYNegative Net Change NBRVPositive Net Change ASLNNegative Net Change
biotechs earnings
Sarepta (SRPT) Q1 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) Q1 revenues increase year over year. The company is progressing well with its pipeline. The company launches its third DMD drug, Vyondys 53, in quarter.
RHHBYNegative Net Change SRPTPositive Net Change NBRVPositive Net Change AVIRPositive Net Change
biotechs earnings
Arena (ARNA) Q1 Earnings Beat Estimates, Etrasimod Progresses
by Zacks Equity Research
Arena Pharmaceuticals (ARNA) beats Q1 bottom-line estimates. The company progresses with the development of its key pipeline candidate, etrasimod.
ARNAPositive Net Change NBRVPositive Net Change AVIRPositive Net Change KNSANegative Net Change
biotechs earnings
Clovis (CLVS) Q1 Earnings Beat, COVID-19 Hurts Rubraca Sales
by Zacks Equity Research
Clovis (CLVS) reports lower-than-expected loss for first-quarter 2021. Lower new patient start amid COVID-19 hurts U.S. sales of Rubraca. Stock up.
BMYNegative Net Change AVIRPositive Net Change
biotechs earnings
Allogene (ALLO) Q1 Earnings & Sales Beat, Pipeline Advances
by Zacks Equity Research
Allogene (ALLO) beats earnings and revenue estimates in the first quarter. Stock gains 1.7%.
NBRVPositive Net Change AVIRPositive Net Change ALLOPositive Net Change
biotechs earnings
Drug/Biotech Stock Q1 Earnings on May 7: RDUS, CRON & OCGN
by Kinjel Shah
Let us take a look at three small biotech companies, RDUS, CRON and OCGN, which are gearing up for their earnings release.
CRONPositive Net Change OCGNPositive Net Change
biotechs pharmaceuticals
Global Blood's (GBT) Q1 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Global Blood (GBT) reports a wider-than-expected loss in the first quarter of 2021 and its revenues also miss estimates.
SNYNegative Net Change GBTPositive Net Change NBRVPositive Net Change ASLNNegative Net Change
biotechs earnings
Horizon's (HZNP) Q1 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Horizon (HZNP) misses estimates for earnings in the first quarter of 2021 while revenues beat the same.
HZNPPositive Net Change NBRVPositive Net Change ALLOPositive Net Change ASLNNegative Net Change
biotechs earnings
ACADIA (ACAD) Q1 Earnings Beat, Revenues Fall Shy of Estimates
by Zacks Equity Research
ACADIA's (ACAD) loss narrows in the first quarter of 2021 while its revenues miss the mark. Robust Nuplazid performance drives the top line year over year.
ACADNegative Net Change NBRVPositive Net Change ALLOPositive Net Change ASLNNegative Net Change
biotechs earnings
Deciphera (DCPH) Q1 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Deciphera (DCPH) posts a narrower loss in the first quarter while sales beat on the encouraging uptake of Qinlock.
IRWDNegative Net Change PFENegative Net Change PCRXNegative Net Change DCPHPositive Net Change
biotechs earnings pharmaceuticals
Myriad Genetics (MYGN) Beats on Q1 Earnings and Revenues
by Zacks Equity Research
Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q1 sales despite pandemic-led business challenges.
CNMDNegative Net Change MYGNNo Net Change BSXPositive Net Change HCANegative Net Change
biotechs earnings medical
Ultragenyx (RARE) Q1 Loss Narrows Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Ultragenyx Pharmaceutical (RARE) Q1 sales increase year over year while loss narrows
PRTANegative Net Change RARENegative Net Change NBRVPositive Net Change AVIRPositive Net Change
biotechs
Top COVID-19 Vaccine Stories of April Put Biotech ETFs in Focus
by Sweta Jaiswal, FRM
Let's take a look at some top coronavirus vaccine stories of April and the possible impact they can have on biotech ETFs.
JNJNegative Net Change AZNNegative Net Change NVAXNegative Net Change IBBNegative Net Change XBINegative Net Change BBHNegative Net Change FBTNegative Net Change BTECPositive Net Change OCGNPositive Net Change IBRXNegative Net Change
biotechs etfs
Incyte (INCY) Q1 Earnings Beat, Sales Miss on Soft Jakafi
by Zacks Equity Research
Incyte (INCY) beats earnings estimates in the first quarter but misses sales figure as Jakafi sales were weaker than expected.
INCYNegative Net Change LLYNegative Net Change NVSNegative Net Change MORPositive Net Change
biotechs earnings pharmaceuticals
Denali's (DNLI) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Denali (DNLI) posts a wider-than-expected loss in the first quarter of 2021 due to higher R&D costs.
BIIBNegative Net Change SNYNegative Net Change DNLINegative Net Change TAKNegative Net Change
biotechs earnings
Repligen (RGEN) Beats on Q1 Earnings & Sales, Raises 2021 View
by Zacks Equity Research
Repligen (RGEN) reports encouraging first-quarter results with sales and earnings beating estimates. The company also raises its guidance for 2021. Stock up.
RGENNegative Net Change NBRVPositive Net Change AVIRPositive Net Change KODPositive Net Change
biotechs earnings
Ligand (LGND) Q1 Earnings Top, Bad Weather Hits Captisol Sales
by Zacks Equity Research
Ligand (LGND) reports mixed first-quarter 2021 numbers with earnings beating estimates but revenues missing the same. Stock down.
SNYNegative Net Change GILDNegative Net Change AMGNPositive Net Change LGNDPositive Net Change
biotechs earnings
CollPlant (CLGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
CollPlant (CLGN) is set to report earnings and revenues, and provide product updates when it releases first-quarter 2021 results.
AERIPositive Net Change CLGNNegative Net Change
biotechs
Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports first-quarter 2021 results.
IRWDNegative Net Change INCYNegative Net Change KALANegative Net Change TLRYPositive Net Change
biotechs marijuana pharmaceuticals
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports first-quarter 2021 results.
IRWDNegative Net Change REGNNegative Net Change SNYNegative Net Change INCYNegative Net Change
biotechs pharmaceuticals
Wall Street Gears for a Hectic Earnings Week
by Zacks Equity Research
Wall Street Gears for a Hectic Earnings Week.
ADPNegative Net Change PFENegative Net Change ELPositive Net Change CVSNegative Net Change MRNANegative Net Change GMNegative Net Change LNegative Net Change CNANegative Net Change DOPositive Net Change ETSYPositive Net Change
auto-tires-trucks biotechs business-services consumer-discretionary consumer-staples insurance internet oil-energy pharmaceuticals
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.
GTHXPositive Net Change AZRXPositive Net Change MISTNegative Net Change OCGNPositive Net Change
biotechs
Moderna (MRNA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are likely to focus on any updated outlook for Modena's (MRNA) authorized coronavirus vaccine and developmental progress with new COVID-19 vaccine candidate on the first-quarter earrings call.
AZNNegative Net Change MRKNegative Net Change MRNANegative Net Change MISTNegative Net Change
biotechs
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.
PFENegative Net Change AXSMPositive Net Change BNTXNegative Net Change MISTNegative Net Change
biotechs